JCI Suppli Fig1 Revised Ver1のコピー
Total Page:16
File Type:pdf, Size:1020Kb
Supplemental Figure 1 A Ptf1a-CreER; KrasG12D; Brg1f/f B Ptf1a-CreER; KrasG12D; Brg1f/f Brg1-positive PanIN Brg1-negative PanIN Brg1-positive PanIN Brg1-negative PanIN Alcian blue Alcian blue / / Brg1 Brg1 p16 p53 Supplemental Figure 1. The tumor suppressor genes p16 and p53 are down-regulated in BRG1-depleted PanINs. (A) Immunohistochemistry of serial sections for BRG1 and p16 in Ptf1a-CreER; KrasG12D; Brg1f/f mice. Arrowheads indicated p16-positive cells. Scale bars: 50μm. (B) Immunohistochemistry of serial sections for BRG1 and p53 in Ptf1a-CreER; KrasG12D; Brg1f/f mice. Scale bars: 50μm. A Supplemental Figure 2 ER Ptf1a Cre Ptf1a CreER Brg1 Brg1 Brg1 Brg1 G12D +Tam Brg1 Kras STOP Kras Kras KrasG12D R172H R172H p53 STOP Trp53 p53 Trp53 STOP d0 6m STOP Tam Sacrifice B R172H f/+ Brg1 ; Trp53 G12D ; Kras ER f/f Brg1 Ptf1a-Cre H&E Brg1 pERK Ki67 C d-14 d0 4m Tam Caerulein Sacrifice ; f/f G12D ;Brg1 ; Kras ER R172H Trp53 Ptf1a-Cre H&E Brg1 pERK Ki67 Supplemental Figure 2. Acinar-specific ablation of Brg1 attenuates PDA formation in the background of oncogenic KRAS and mutant p53. (A) The genetic strategy used to delete Brg1 and activate oncogenic Kras and mutant p53 in adult pancreatic acinar cells, in addition to experimental design for tamoxifen administration and analysis. (B) H&E staining and immunohistochemistry for BRG1, phospho-ERK and Ki67 of PDAs in Ptf1a-CreER; KrasG12D; Trp53R172H; Brg1f/f mice and littermate controls. Scale bars: 50μm. (C) Upper: Experimental design for tamoxifen administration, caerulein acute pancreatitis and analysis. Lower: H&E staining and immunohistochemistry for BRG1, phospho-ERK and Ki67 of PDAs in caerulein treated Ptf1a-CreER; KrasG12D; Trp53R172H; Brg1f/f mice. Scale bars: 50μm. Supplemental Figure 3 A B * ** 2 WT Ptf1a-Cre; 30 Brg1f/f 1.5 WT ****** * *** 20 1 f/f (% of ADM) +Tgf-α 10 0.5 0 0 Tgf-α - + - + Relative expression of mRNA Ptf1a-Cre; Brg1 WT Ptf1a-Cre; Brg1f/f acinar duct progenitor marker marker marker C D KrasG12D; Brg1f/f / KrasG12D 50 *** 2 40 Acvr2b Clu Rfx3 Sox4 Glis3 Foxo1 Ptpn6 Insr Invs Igf1r Bglap2 Il6ra Nkx2-2 Xbp1 Sox9 Ptf1a Eif2ak3 Selt Smad2 Kras 30 1 Pdx1 20 Pde3b Ad-Cre f/f 1/2 Onecut2 (% of ADM) 10 1/4 0 Kras; Brg1 Kras Kras; Brg1f/f Microarray mRNA fold change 1/8 Supplemental Figure 3. Primary acinar cell culture reveals that Brg1 promotes Sox9 expression. (A) Left: Brightfield images of acinar cell clusters from WT and Ptf1a-Cre; Brg1f/f mice after 5 days of culture in collagen gel with TGF-α. Scale bars: 50μm. Right: Quantification of cystic ductal strictures in 3D-cultured acinar cell clusters from WT and Ptf1a-Cre; Brg1f/f mice after 5 days of culture in collagen gel with or without TGF-α. n=3 per genotype; means ± SEM are shown. * P < 0.05, Student’s t test. (B) RT-PCR analysis of isolated acini from WT and Ptf1a-Cre; Brg1f/f mice. Genes important for pancreatic development and maintenance of pancreatic lineages are examined. n=3 per genotype; means ± SEM are shown. * P < 0.05, ** P < 0.01, and *** P < 0.001, Student’s t test. (C) Left: Brightfield images of acinar cell clusters from KrasG12D and KrasG12D; Brg1f/f mice after 5 days of culture in collagen gel. Cells were infected with Ad-Cre on day 0. Scale bars: 50μm. Right: Quantification of cystic ductal strictures in 3D-cultured acinar cell clusters from Ad-Cre-infected KrasG12D and KrasG12D; Brg1f/f acini after 5 days of culture in collagen gel. n=3 per genotype; means ± SEM are shown. *** P < 0.001, Student’s t test. (D) Fold changes in the expression of genes implicated in pancreas development and maintenance of pancreatic differentiation for Ad-Cre-infected KrasG12D; Brg1f/f acini after 24h of culture relative to control Ad-Cre-infected KrasG12D acini after 24h of culture. Supplemental Figure 4 A WT 1.6 Ptf1a-Cre; Brg1f/f 1.4 1.2 1 0.8 0.6 0.4 0.2 0 (Relative expression of mRNA) Supplemental Figure 4. Expression of upstream regulators of Sox9 in the pancreas is not significantly changed in Brg1-depleted acinar cells (A) RT-PCR analysis of Sox9 upstream regulators in isolated acini from WT and Ptf1a-Cre; Brg1f/f mice. n=3 per genotype; means ± SEM are shown. Student’s t test. Supplemental Figure 5 A Ptf1a-CreER; KrasG12D; Sox9OE; Brg1f/f Alcian blue / Brg1 Brg1-positive PanIN Brg1-negative PanIN B 185-fold change 267-fold change * 8 * 15 7 6 10 5 4 3 5 BRG1-positive BRG1-negative 2 1 Alcian blue positive area (%) 0 Alcian blue positive area (%) 0 Ptf1a-CreER; Ptf1a-CreER; Ptf1a-CreER; Ptf1a-CreER; Kras; Brg1f/f Kras; Sox9OE; Kras; Brg1f/f Kras; Sox9OE; Brg1f/f Brg1f/f Supplemental Figure 5. Sox9 overexpression accelerates KRAS-driven PanIN formation in mice. (A) Immunohistochemistry for BRG1 and alcian blue staining of Ptf1a-CreER; KrasG12D; Sox9OE; Brg1f/f mice. Representative BRG1-positive and BRG1-negative PanINs from the same sample are shown. Scale bars: 50μm. (B) Quantification of BRG1-positive and BRG1-negative PanINs in Ptf1a-CreER; KrasG12D; Brg1f/f mice and Ptf1a-CreER; KrasG12D; Sox9OE; Brg1f/f mice. n=3-4 mice per genotype; means ± SEM are shown. * P<0.05, Student’s t test. Supplemental Figure 6 A (8-16w old) day0 day3 Tam Sacrifice B Pdx1-FLP; FSFKrasG12D Pdx1-FLP; FSFKrasG12D; FSF-R26CAG-CreERT2; Brg1f/f 2.5 * 2 1.5 CC3 1 0.5 CC3 positive cells / PanIN 0 Pdx1-FLP; FSFKrasG12D Pdx1-FLP; FSFKrasG12D; FSF-R26CAG-CreERT2; Brg1f/f Supplemental Figure 6. Loss of BRG1 in established PanIN results in its apoptosis. (A) Experimental design for tamoxifen administration and analysis. (B) Immunohistochemistry for cleaved caspase 3 (CC3) in Pdx1-Flp; FSF-KrasG12D and Pdx1-Flp; FSF-KrasG12D; FSF-R26CAG-CreERT2; Brg1f/f mice 3 days after tamoxifen injection. Scale bars: 200μm. Right bar graphs are quantification for CC3 positive cells per PanIN lesion. n=3 per genotype; means ± SEM are shown. *P<0.05, Student’s t test. Supplemental Figure 7 A B PDA_2 PDA_3 PDA_1 PDA_2 PDA_3 PDA_4 PDA_5 ● ● ● ●● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ●● ● TP53 Nonsense mutation ● ● ●●● ● ● ● ●●● ● ● ● ● ●● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ●● ● ● ● ●●● ● ● ●●● ● ●● ● ●●● ● ●●● ●● ● ●● ● ●●● ● ● ●● ● ● ● ● total CN KRAS Frameshift insertion/deletion total CN 0 2 4 CDKN2A Missense mutation 0 2 4 TGFBR2 Multiple mutation hetero hetero BRG1 Homozygous deletion SNPs SNPs Deletion ● ● ● ● ●● ●●● ● ● ●● ● ● ● ●● ●● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ●● ● ● ●● ● ● Loss of heterozygosity ● ● ● ●●● ●● ● ●● ●●● ● ● ● AsCN ● AsCN 0 1 2 0 1 2 C * 5000 ● 4000 3000 BRG1 Deletion Diploid 2000 Relative expression 1000 ● 0 Deletion Diploid BRG1 Supplemental Figure 7 Result of targeted sequence of BRG1-low human PDA samples (A) Mutational landscape of BRG1-low human PDA samples. KRAS, TP53, CDKN2A and TGFBR2 are shown as quality controls. Deletion of BRG1 is detected in 2 of 5 BRG1-low human PDA samples. (B) Detail of loss of chromosome 19p in PDA_2 and PDA_3. Total copy number (total CN) and allele specific copy number (AsCN) are shown. Copy number abnormalities are shown as black bar. Red triangle shows where BRG1 is located on. (C) Relationship between deletion of BRG1 and BRG1 mRNA expression from a cohort of 76 high purity samples in the TCGA data set. In the box-and-whisker plots, horizontal bars indicate the medians, boxes indicate 25th to 75th percentiles, and whiskers indicate minimum to maximum without outlier. *P<0.05, Mann-Whitney U test. Supplemental Figure 8 A B 8 9 SOX9 7.5 *** * 7 8 6.5 7 6 5.5 r=0.303 6 5 5 4.5 Relative mRNA expression 4 4 Relative mRNA expression of 5.5 6 6.5 7 7.5 Relative mRNA expression of BRG1 High Low High Low BRG1 BRG1 BRG1 BRG1 BRG1 SOX9 Supplemental Figure 8 BRG1 expression correlates with SOX9 expression in human PDAs. (A) Plots of mRNA expression of BRG1 and SOX9 from a cohort of 96 patients in QCMG data set. (B) The box-and-whisker plot demonstrates the differential expression for SOX9 between the BRG1-high (n =71, the higher 75%) and BRG1-low groups (n = 25, the lower 25%) from a cohort of 96 patients in the QCMG data set. In the box-and-whisker plots, horizontal bars indicate the medians, boxes indicate 25th to 75th percentiles, and whiskers indicate minimum to maximum without outlier. * P < 0.05 and *** P < 0.001, Student’s t test. Supplemental Table 1: Differently expressed genes in Kras G12D vs. Brg1 f/f acinar cell explants up down gene symbol fold change (log) gene symbol fold change (log) S100a6 3.7695728 G6pc2 -4.3786884 Krtap16-1 3.4862444 Fgl1 -3.9309574 Pecam1 3.46082 Lgals4 -3.1478798 Plvap 3.3369914 Ncor1 -3.1447362 Vaultrc5 2.9253636 Csrnp1 -3.12215 D8Ertd158e 2.8899298 Pdyn -3.1156846 Sprr1a 2.8063721 Espn -3.0293398 Cfb 2.7875106 Scg2 -2.9722324 Pxdn 2.7104712 Cyp2s1 -2.9414282 Zdhhc1 2.7012344 Slc39a10 -2.9306106 Ruvbl2 2.6697236 Zfp207 -2.9113906 Col1a1 2.549479 Rbm25 -2.8066914 Cxxc4 2.5407706 Hif3a -2.775671 Sprr2b 2.5220404 Ins1 -2.7639676 C5ar2 2.5090246 Ctsc -2.7582578 Parp3 2.5035262 Cib1 -2.7560214 Crhr1 2.4913382 Nnat -2.7315292 Tbc1d21 2.4566574 Fxyd3 -2.7256318 Oasl1 2.4398156 Nol3 -2.6992188 Sox15 2.411714 Kif5c -2.669723 Ecscr 2.3602772 Ins2 -2.6675257 Pglyrp1 2.3591118 Cyp2b10 -2.6431714 Vim 2.3278822 Crem -2.6197104 Atp1a3 2.317926 Hnrnpu -2.5793944 Rnase4 2.3134738 Smarca4 -2.5635176 Fhl2 2.3066534 Slco2b1 -2.5530882 Tiam1 2.303306 Espn -2.5276976 Fut4 2.302178 9530006C21Rik -2.5276084 Flna 2.2909526 Spock2 -2.5149002 Col4a2 2.283824 Gpr161 -2.507926 Cfb 2.246233 Rlf -2.5061864 Olfr700 2.237329 Ptprn -2.4990774 Sprr2k 2.2317066 Camta1 -2.4960784 Zmynd10 2.229248 Spaca6 -2.4613834 Ubash3b 2.21154 Oas1b -2.4521666 Stk10 2.1982666 Mrpl24 -2.4520208